Novo has cut the price of its obesity drug Wegovy in Sweden by 20%, effective October 1. Patients currently pay for the treatment out of pocket, and the company says the cut is meant to help more people stay on treatment over time.

Danish biotech Breye Therapeutics has closed an oversubscribed EUR 67.5 million Series A financing to advance danegaptide, its first-in-class oral treatment for non-proliferative diabetic retinopathy (NPDR), into a Phase II clinical trial.

Egetis Therapeutics has received FDA approval for Emcitate (tiratricol), making it the first approved treatment in the US for patients with the rare genetic disease MCT8 deficiency. With the approval, the company also received a Rare Pediatric Disease Priority Review Voucher.

Umeå-based biotech Omnio has raised EUR 2.9 million in an oversubscribed round from existing investors and shareholders. The funding will move the company’s plasminogen-based therapy for hard-to-heal chronic wounds closer to clinical trials, with patient studies planned for 2027.

The company has signed a new contract with a leading US hospital network that operates multiple hospitals in the eastern United States. The contract covers an initial installation of 60 next-generation TetraGraph systems for monitoring patients under anaesthesia.

Arjo has presented a new strategy at its Capital Markets Day, committing to improve EBIT by approximately SEK 350 million (±25 million) compared with 2025, by mid-2029.

Södertälje-based Anocca has dosed the first patient in Sweden with its TCR-T cell therapy, which targets KRAS G12V mutations in pancreatic cancer. Sweden is the third European country where a patient has received the therapy.

Hansa Biopharma has signed a collaboration with Amsterdam-based Cradle. Hansa will use Cradle’s AI-driven protein design and engineering platform across its research and development work to develop new immunomodulatory treatments for severe autoimmune diseases.

Swedish biotech company MucoShield is developing a locally administered, fast-acting treatment to protect the oral mucosa during chemotherapy and prevent severe chemotherapy-induced oral mucositis, one of the most painful and debilitating side effects of cancer treatment.

Karolinska Institutet’s Center for Systems Infection Biology (CSIB) is being inaugurated today, October 2, at Campus Flemingsberg.

SciLifeLab is increasing its space on Campus Solna by more than 9,000m². Property owner Akademiska Hus is investing approximately SEK 230 million in an extensive renovation that will give the research center more modern laboratories, flexible workspaces, and new facilities for meetings and training.

Cancer rates among adults under 50 rose for 12 of 18 cancer types in the Nordic countries between 2003 and 2022, according to a registry study published in The Lancet Regional Health – Europe. The study analyzed more than 2.2 million cancer cases from Sweden, Denmark, Finland, Iceland, Norway, the Faroe Islands and Greenland, covering nearly 28 million people.